Silent myocardial ischemia: clinical characteristics, underlying mechanisms, and implications for treatment.
A great deal of interest is being generated by the possibility that patients with coronary artery disease and typical angina pectoris may also experience periods of ischemia during activities of daily living that are not necessarily associated with angina or increased myocardial oxygen demand. It might be that the majority of ischemic episodes during daily life are not preceded by increases in myocardial oxygen demand, and are probably related to dynamic changes in coronary blood flow. Questions still remain, however, regarding the prevalence of asymptomatic ischemia in patients who present with effort angina and positive results on exercise tolerance tests. Therefore, in susceptible patients with coronary artery disease, calcium channel blockers, especially nifedipine, may be of particular benefit since they decrease myocardial oxygen demand during effort and may increase coronary blood flow, thereby aborting asymptomatic ischemia, which tends to occur at low levels of cardiac oxygen demand. It appears that a greater awareness of the total ischemic burden, i.e., the sum total of symptomatic and asymptomatic and exertional and nonexertional ischemia, may facilitate individualization of therapy for patients with coronary artery disease. Agents that both reduce myocardial oxygen demand and improve coronary blood flow, such as nifedipine, may particularly benefit individuals whose ischemia may be both asymptomatic and symptomatic, and who seem to constitute the majority of patients with coronary artery disease.
D000789:Angina, Unstable / Q000150:complications; D003326:Coronary Circulation; D003327:Coronary Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D004562:Electrocardiography; D005080:Exercise Test; D005500:Follow-Up Studies; D006339:Heart Rate; D006801:Humans; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000209:etiology; D009543:Nifedipine / Q000627:therapeutic use; D011379:Prognosis
D009543:Nifedipine